News NICE lifts restrictions on Ferring prostate cancer drug Decision followed a successful appeal by manufacturer.
Debates & Insight Sponsored Available on demand: Cancer Treatment Access: Strategy, Appr... Available on demand: A one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
Articles NICE and Highly Specialised Technologies: three years on Leela Barham examines the process for the appraisal of Highly Specialised Technologies.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
